Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.43 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.42 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 2/20 | 0.42 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.40 |
| ▸ | GRB2 | P62993 | 1/20 | 0.39 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.39 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.39 |
| ▸ | NTMT1 | Q9BV86 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30069733 | 0.90 | OPRM1 (0.54) | OPRM1F2OPRD1NTSR1NTSR2 | |
| SCHEMBL29495157 | 0.90 | CXCR4 (0.51) | OPRM1OPRD1CXCR4NMUR2NMUR1 | |
| SCHEMBL29886085 | 0.89 | EPHA2 (0.49) | OPRM1OPRD1CXCR4NMUR2NMUR1 | |
| SCHEMBL31633428 | 0.87 | CXCR4 (0.54) | CXCR4NMUR2NMUR1 | |
| SCHEMBL29677082 | 0.87 | F2 (0.49) | OPRM1F2OPRD1NTSR1NTSR2 | |
| SCHEMBL20764559 | 0.86 | OPRM1 (0.52) | OPRM1F2OPRD1NTSR1NTSR2 | |
| SCHEMBL2317887 | 0.86 | CXCR4 (0.48) | OPRM1OPRD1CXCR4NMUR2NMUR1 | |
| SCHEMBL28923776 | 0.86 | CXCR4 (0.48) | OPRM1OPRD1CXCR4NMUR2NMUR1 | |
| SCHEMBL2317896 | 0.86 | CXCR4 (0.48) | OPRM1OPRD1CXCR4NMUR2NMUR1 | |
| SCHEMBL29367074 | 0.86 | BDKRB2 (0.50) | OPRM1F2OPRD1NTSR1NTSR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4055165-A1 | TRANSTHYRETIN (TTR) IRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES | Alnylam Pharmaceuticals, Inc. (US) | 2022-09-14 | — | — | EP | claimed |